Astellas/Seagen prepare full US filing of bladder cancer dru...

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.

Merck, Pfizer get EU nod for Bavencio as bladder cancer main...

Pfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor Bavencio as a first-line maintenance therapy for bladder cancer, stealing a marc

AZ aims to cut cancer clinic visits with new Imfinzi regimen

The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic visits for patients wit

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

Merck & Co's Keytruda fails in first line bladder cancer

Merck & Co’s bid to become standard care in untreated bladder cancer has run into trouble after its Keytruda failed to outperform chemotherapy in this lucrative indication. 

Seattle Genetics says data backs Padcev combo for first-line...